about
Elucidating human male germ cell development by studying germ cell cancerThe bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo.Transcription factor TFAP2C regulates major programs required for murine fetal germ cell maintenance and haploinsufficiency predisposes to teratomas in male miceAnalysis of TET expression/activity and 5mC oxidation during normal and malignant germ cell development.Reference gene validation for RT-qPCR, a note on different available software packages.BMP Inhibition in Seminomas Initiates Acquisition of Pluripotency via NODAL Signaling Resulting in Reprogramming to an Embryonal CarcinomaXenografting of Cancer Cell Lines for In Vivo Screening of the Therapeutic Potential of HDAC Inhibitors.Re-visiting the Protamine-2 locus: deletion, but not haploinsufficiency, renders male mice infertile.SOX2 is essential for in vivo reprogramming of seminoma-like TCam-2 cells to an embryonal carcinoma-like fate.A signaling cascade including ARID1A, GADD45B and DUSP1 induces apoptosis and affects the cell cycle of germ cell cancers after romidepsin treatment.The role of BLIMP1 and its putative downstream target TFAP2C in germ cell development and germ cell tumours.The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomasAre testicular mast cells involved in the regulation of germ cells in man?The plasticity of germ cell cancers and its dependence on the cellular microenvironment.Establishment of a versatile seminoma model indicates cellular plasticity of germ cell tumor cells.TGF-β1, EGF and FGF4 synergistically induce differentiation of the seminoma cell line TCam-2 into a cell type resembling mixed non-seminoma.TCam-2 but not JKT-1 cells resemble seminoma in cell culture.MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy.Brentuximab vedotin exerts profound antiproliferative and pro-apoptotic efficacy in CD30-positive as well as cocultured CD30-negative germ cell tumour cell lines.Tpbpa-Cre-mediated deletion of TFAP2C leads to deregulation of Cdkn1a, Akt1 and the ERK pathway, causing placental growth arrest.c-KIT is frequently mutated in bilateral germ cell tumours and down-regulated during progression from intratubular germ cell neoplasia to seminoma[Embryonal germ cells and germ cell tumors]TCam-2 Cells Deficient for SOX2 and FOXA2 Are Blocked in Differentiation and Maintain a Seminoma-Like Cell Fate In Vivo.Unique and redundant roles of SOX2 and SOX17 in regulating the germ cell tumor fateEpigenetic drugs and their molecular targets in testicular germ cell tumoursManagement, Treatment, and Molecular Background of the Growing Teratoma SyndromeARID1A Regulates Transcription and the Epigenetic Landscape via POLE and DMAP1 while ARID1A Deficiency or Pharmacological Inhibition Sensitizes Germ Cell Tumor Cells to ATR Inhibition[Current research on pediatric and adult germ cell tumors : A report from the first "Düsseldorfer Testis Cancer Day"]N6-Methyladenosine detected in RNA of testicular germ cell tumors is controlled by METTL3, ALKBH5, YTHDC1/F1/F2, and HNRNPC as writers, erasers, and readersEpigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerationsDeciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectorsCDK4/6 inhibition presents as a therapeutic option for paediatric and adult germ cell tumours and induces cell cycle arrest and apoptosis via canonical and non-canonical mechanismsTargeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines
P50
Q28074242-F4356F03-613B-4994-B1AC-2CF5D67F3E99Q33844624-00F0B13B-D110-440C-9C0F-94FC94CBC07AQ34963433-66533E7B-DDDE-41B4-8AC1-8C4D5509BDFBQ35080075-72593B95-1062-4827-9E0A-4D795ACDF424Q35590844-391B7BBB-2A73-4C06-ADB8-91A4DA3F13FFQ35727303-35C3B423-2E7A-4DF9-B8B0-04BB44D72C4BQ36168641-D012D8CD-5A18-4B39-A4A6-057E4E8BB7B3Q37408427-4882DCDD-1E33-4BB7-8426-1C1726B0B181Q37565051-00652C51-BB51-4FE9-AFFA-83F6B8A8092EQ37688873-44B747CE-43BA-4897-87CD-9F90F6E1208AQ37874665-8B0DAA72-867F-4018-B38A-C55A8CFE4CBFQ38756704-A55B6128-226A-4620-90F4-F019DC479C01Q38985838-EEA258E3-90B3-49A0-9193-D6AE05715C9AQ39154300-7917C509-BAAE-45A6-99F4-1BD5560D6E6BQ39367088-26D5FEA2-3173-4090-86AF-6F17CC908026Q39529163-96408D41-39B5-45E8-A82A-EA48B2CA6092Q40050312-9FDF44F8-9D8C-4DC7-A4B0-01B556843755Q40157247-7AE1A5CF-4CC6-48F9-B10A-D0B559B9B05FQ47098861-FAA46B1A-97D5-4FA2-93E9-D52BB3700CEAQ50538133-46662F21-4E6D-4A47-86E7-39562D623ADEQ58194329-D1F3B293-7C62-4145-9A62-F3A3EB94E702Q58194334-469E2482-8C51-46F2-BD1E-E8021959C516Q64950552-FDB8FC0A-6625-4822-91DA-FC5E5507A200Q90474073-BCD79B2C-56FB-4AA4-9A51-EC26EF38BBBDQ91597768-A4FD6FF3-1DCA-4CB5-B16A-018BC9249809Q91660922-847B24F0-55D0-4788-86AB-7EF463EDEF81Q91781345-2C346B31-5FCB-40D1-AC7F-5AD2471ECFE6Q92231550-7E39C4EA-B26D-4277-8F3E-01E68BB09F8BQ92569120-4EBE6E62-065C-4DBF-8AF8-762B36287FC2Q92695854-3217D89A-670B-4760-83C6-8535A12A76E7Q93262010-ADBF049F-D836-4BC5-B226-E21644C75E4FQ94957222-41EABF0D-048C-4ED0-AD93-FE5D83F31ED2Q95302912-9AA530A9-4C4B-460F-BD39-05FB87F3652B
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel Nettersheim
@ast
Daniel Nettersheim
@en
Daniel Nettersheim
@es
Daniel Nettersheim
@fr
Daniel Nettersheim
@nl
Daniel Nettersheim
@sl
type
label
Daniel Nettersheim
@ast
Daniel Nettersheim
@en
Daniel Nettersheim
@es
Daniel Nettersheim
@fr
Daniel Nettersheim
@nl
Daniel Nettersheim
@sl
prefLabel
Daniel Nettersheim
@ast
Daniel Nettersheim
@en
Daniel Nettersheim
@es
Daniel Nettersheim
@fr
Daniel Nettersheim
@nl
Daniel Nettersheim
@sl
P108
P1053
M-9249-2013
P106
P2013
DevelopmentalPathologyBonn
P21
P31
P3829
P496
0000-0002-4483-845X